Trillium Asset Management LLC increased its holdings in shares of Haleon PLC Sponsored ADR (NYSE:HLN – Free Report) by 44.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 353,378 shares of the company’s stock after buying an additional 107,951 shares during the quarter. Trillium Asset Management LLC’s holdings in Haleon were worth $3,180,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also recently added to or reduced their stakes in the business. Parkside Financial Bank & Trust grew its holdings in Haleon by 20.4% in the 2nd quarter. Parkside Financial Bank & Trust now owns 6,233 shares of the company’s stock valued at $58,000 after buying an additional 1,055 shares during the period. Sterling Capital Management LLC increased its stake in shares of Haleon by 1.9% during the 3rd quarter. Sterling Capital Management LLC now owns 88,039 shares of the company’s stock valued at $792,000 after acquiring an additional 1,624 shares during the last quarter. Ethic Inc. increased its stake in shares of Haleon by 1.5% during the 3rd quarter. Ethic Inc. now owns 111,428 shares of the company’s stock valued at $1,003,000 after acquiring an additional 1,658 shares during the last quarter. Diversify Advisory Services LLC increased its stake in shares of Haleon by 7.7% during the 3rd quarter. Diversify Advisory Services LLC now owns 24,023 shares of the company’s stock valued at $239,000 after acquiring an additional 1,711 shares during the last quarter. Finally, Allen Capital Group LLC lifted its holdings in shares of Haleon by 14.5% during the 1st quarter. Allen Capital Group LLC now owns 13,628 shares of the company’s stock worth $136,000 after acquiring an additional 1,729 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on HLN shares. Morgan Stanley reissued an “overweight” rating on shares of Haleon in a research report on Thursday, August 6th. Wall Street Zen downgraded shares of Haleon from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Zacks Research lowered shares of Haleon from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 22nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research report on Friday, September 25th. Finally, Berenberg Bank reaffirmed a “buy” rating on shares of Haleon in a research note on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $4.90.
Get Our Latest Research Report on Haleon
Haleon Price Performance
Shares of Haleon stock opened at $9.18 on Monday. Haleon PLC Sponsored ADR has a twelve month low of $8.38 and a twelve month high of $11.28. The stock has a market capitalization of $40.41 billion, a P/E ratio of 23.53, a PEG ratio of 2.15 and a beta of 0.15. The company has a current ratio of 0.69, a quick ratio of 0.52 and a debt-to-equity ratio of 0.38. The business’s fifty day moving average price is $9.34 and its 200 day moving average price is $9.72.
Haleon Profile
Haleon plc is a global consumer healthcare company that develops and sells nonprescription health products. Its portfolio spans oral health, pain relief, vitamins and supplements, respiratory health, digestive health, and therapeutic skin care. Its brands include Sensodyne, parodontax and Polident in oral care; Advil, Panadol and Voltaren for pain relief; and Centrum, Emergen-C and Theraflu in supplements and respiratory care. Haleon sells its products in markets around the world. Haleon became an independent public company in 2022 after separating from GSK.
See Also
- Five stocks we like better than Haleon
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.
